Skip to main content

Pharmacotherapy: Diabetes Mellitus-Insulin Therapy!

PHARMACOTHERAPY

Medications classifications include:

  1.  Sulfonyl Urea's
  2. Nonsylfonylurea Secretagogues (a-Glinides)
  3. Biguanides
  4. Thiazolidinediones
  5. a-Glucosidase Inhibitors
  6. Dipeptidyl Peptidase-4 Inhibitors (Gliptins)
  7. Sodium-glucose co-transporter (SGLT) Inhibitors 
  8. Central-Acting Dopamine Agonists
  9. Bile Acid Sequestrants
  10. Insulin therapy

10. INSULIN THERAPY

  • Insulin is used for the primary treatment in T1DM.
  • Insulin is used in all types of DM and has no specific maximum dose.
  • Insulin is the primary treatment in T1DM, and injected amylin can be added to decrease fluctuations in blood glucose levels.
  • Insulin is available in various formulations. Most formulations are available as U-100, indicating a concentrations of 100unit/mL.

Types:

  • Insulin is divided into two main classes:

                1. Basal Insulin                                                                             2. Bolus insulin

Storage:

  • Insulin is typically refrigerated, and most vials are good for 28 days at room temperature
  • Insulin detemir can be stored at room temperature for 42 days.

Route of Administration:

  • Most common route of administration is Subcutaneous injection using a syringe or a pen device.
  • Patients should be educated to rotate their site of injection administrations to minimize lipohypertrophy(a buildup of fat that decreases or prevents proper insulin absorption).
  • The fastest absorption occurs in the Abdomen and the slowest in the buttocks.

Insulin Devices:

  • Insulin syringes are distinguished according to the syringe capacity, syringe markings, needle Guage and length.
  • Insulin pens are self-contained systems of insulin delivery. The primary advantage of Pen system is that patients do not have to draw up the dose from the Insulin vial.


*Only Insulin that can be administered IV -- Regular or Human Insulin*

*Rapid Acting Insulins are-- Insulin Aspart, Insulin Glulisine, Insulin Lispro*


1.BOLUS INSULIN (covers insulin response to meals):

Regular Insulin:

  • Regular insulin is unmodified crystalline insulin commonly referred to as Neutral or Human Insulin.
  • It is a clear solution that has relatively short onset and duration of action and is designed to cover insulin response to meals.
  • On SC injection, Regular insulin forms small aggregates called Hexamers that undergo conversion to Dimers followed by Monomers before systemic absorption can occur.
  • Patients should be counselled to inject insulin SC 30 minutes before consuming a meal.
  • It is the only insulin administered IV.
  • Three rapidly acting insulins approved by United States are Aspart, Glulisine, and Lispro. Substitution of one or two amino acids in regular insulin results in the unique pharmacokinetic properties characteristics of these agents.

2.Basal Insulin (Covers insulin response in between the meals and overnight):

Intermediate Duration Insulin:

  • Neutral Protamine Hagedorn, better known as NPH insulin is prepared by a process in which protamine is conjugated with regular insulin, rendering a product with delayed onset but extended duration of action and is designed to cover insulin requirements between meals and/or overnight.
  • With the advent of the long-acting insulins, NPH insulin use has been declined because of the inability to predict accurately when peak effects occur and a duration of action less then 24hr.
  • Additionally, Protamine is a foreign protein that may increase the possibility of an allergic reaction.
  • NPH insulin can be mixed with regular insulin and used immediately or stored for future use up to 1 month at room temperature or 3 months in refrigerator.
  • NPH can be mixed with either Aspart or Lispro insulins, but it must be injected immediately after mixing.
  • Whenever mixing insulin products with NPH, the shorter acting insulin should be drawn into the syringe first.

Long-duration Insulin:

Glargine and Detemir are designed once daily dosing basal Insulin.

  • Insulin Glargine differs from regular insulin by three amino acids, resulting in a low solubility at physiologic pH.
  • Detemir binds to albumin in the plasma, which gives it sustained action.
  • Neither Glargine nor Detemir can be administered IV or mixed with other insulin products.
  • Both Glargine and Detemir have been shown to produce slower, more prolonged absorption and a relatively constant concentration over 24hr as compared with NPH.

Combination Insulin Products:

  • NPH is available in combinations of 70/30 (70% NPH & 30% Regular insulin). and 50/50 (50% NPH & 50% Regular insulin).
  • Two short-acting insulin analog mixtures are also available;

  1. Humalog mix 75/25 contains 75% insulin lispro protamine suspension and 25% insulin lispro.
  2. Novolog mix 70/30 contains 70% insulin aspart protamine suspension and 30% insulin aspart.


Comments

Popular posts from this blog

General Mechanism of Actions of INSULIN.

GENERAL MECHANISM OF ACTION OF INSULIN AND RELATE HORMONES The body's main fuel is Glucose. Glucose is stored in the liver and muscles as Glycogen.  Excess glucose is stored in the adipose tissues which yield fatty acids via lipolysis. In the fasting state, free fatty acids supply much of the energy needs of the body except for the CNS which requires Glucose to function normally. Proteins can also be converted to glucose via gluconeogenesis. RELEASE OF INSULIN AND GLUCAGON Insulin and Glucagon are produced in the pancreas by the Islets of Langerhans . Beta cells   make up 70%-90% of the Islets and produce Insulin and Amylin while the a-cells   produce glucagon. The main function of insulin is to decrease blood glucose levels. Glucagon, along with other counter-regulatory hormones such as growth factor, cortisol, and Epinephrine, increases Blood glucose levels.  The opposing actions of Glucagon and Insulin along with other counter-regulatory hormones maintain a norma...

Diabetes Mellitus: Its Goals Of Therapy!

  GOAL OF THERPY The goals of treatment of DM includes; Reducing, controlling and managing long-term microvascular, macrovascular and neuropaathic complications. Preserving beta cell function. Preventing acute complications from increased Blood glucosel level. Minimizing hypoglycemic episodes. Maintaining patient quality of life. --Two landmark trials, THE DIABETES CONTROL AND COMPLICATION TRIAL (DCCT) and THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY(UKPDS), showed that lowering blood glucose levels decreased the risk of developing chronic complications. --A near normal blood glucose level can be achieved with appropriate patient education , lifestyle modification and medications . --Proper care of DM requires goal setting and assessment for glycemic control , self-monitoring of blood glucose (SMBG) monitoring of blood glucose pressure , and lipid levels , regular monitoring for the development of complications , dietary and exercise lifestyle modifications and proper medicatio...

Diabetes Mellitus: Clinical Presentation and Diagnosis!

 CLINICAL PRESENTATION AND DIAGNOSIS OF DM 2. SCREENING American Diabetes Association (ADA) recommends routine screening for T2 DM every 3 years in all adults starting at 45 years of age. Testing of T2 DM should be considered in any adult, regardless of their age, who have a BMI greater than or equal to 25kg/m2. The ADA does not currently recommend widespread screening for T1 DM because of the relatively low incidence in the general population, although measurement of Islet antibodies may be appropriate for high-risk individuals. 3.GESTATIONAL DIABETES: "Gestational diabetes is the glucose intolerance in women during pregnancy". All pregnant women who have risk factors for T2 DM should be screened for undiagnosed T2 DM at their first prenatal visit using standard diagnostic criteria.  Any women found to have diabetes in the early point at pregnancy is considered to have T2 DM or GDM. All other pregnant women, not currently known to have DM should be screened for GDM with a 75...